Aclarion Has Completed The First Nociscan Exams For Patients Enrolled In LIFEHAB Trial In Norway Studying 202 Patients With Low Back Pain Greater Than 1 Year In Duration And Will Compare Treatment Outcomes Between Lumbar Interbody Fusion Surgery And Multidisciplinary Rehabilitation
Portfolio Pulse from Benzinga Newsdesk
Aclarion has completed the first Nociscan exams for patients in the LIFEHAB trial in Norway. The trial involves 202 patients with chronic low back pain and will compare outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation.
September 10, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclarion has completed initial Nociscan exams in a significant trial in Norway, potentially impacting future treatment protocols for chronic low back pain.
The completion of the first Nociscan exams in the LIFEHAB trial marks a significant milestone for Aclarion. This trial could influence future treatment protocols for chronic low back pain, potentially increasing demand for Aclarion's Nociscan technology. The news is likely to positively impact Aclarion's stock in the short term as it demonstrates progress in a major clinical trial.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90